Company Deep Dive
Business segments breakdown, earnings transcript analysis, management credibility scoring, competitive landscape, and scenario modelling.
ANTX
SellHot AirAN2 Therapeutics, Inc. · Healthcare · United States · $211M · Avg Vol: $1M/d
COMPANY DESCRIPTION
AN2 Therapeutics, Inc. is a clinical-stage biopharmaceutical company dedicated to developing innovative therapies for serious infectious diseases, with a primary focus on difficult-to-treat non-tuberculous mycobacteria (NTM) infections. The company's competitive edge lies in its novel drug candidates targeting unmet medical needs, leveraging deep scientific expertise to advance its pipeline.
FINANCIAL SUMMARY (USD)
| Year | 2021 | 2022 | 2023 | 2024 | 2025 | CAGR | TTM | 2026E | 2027E | Fwd CAGR |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | — | 0 | 0 | 0 | 0 | — | — | — | — | — |
| EPS | — | -2.79 | -2.74 | -1.72 | -1.16 | — | -1.05 | -0.90 | -0.80 | — |
| Shares | — | 19.4M | 29.7M | 29.9M | 27.4M | +41.3% | — | — | — | — |
| Debt | 0 | 53.0K | 0 | — | — | — | — | — | — | — |
| Equity | — | 95.4M | 124.7M | 81.8M | 53.1M | -17.8% | — | — | — | — |
| Op CF | — | -33.5M | -53.3M | -49.3M | -29.8M | — | -30.7M | — | — | — |
| Inv CF | — | -21.8M | -43.3M | 54.6M | 28.3M | — | — | — | — | — |
| Fin CF | — | 70.4M | 85.0M | 0.4M | 0.1M | — | — | — | — | — |
SCORE BREAKDOWN
FUNDAMENTALS
SECTOR PEERS
Closest peers in Healthcare, ranked by industry match, size, and score similarity. Cross-listings of ANTX are excluded.
| Ticker | Company | Mkt Cap | StockRank | Signal |
|---|---|---|---|---|
| ANTX | AN2 Therapeutics, Inc.(you) | $211M | 35 | Sell |
| ACOG | Alpha Cognition Inc. Common Stock | $199M | 34 | Sell |
| DTIL | Precision BioSciences, Inc. | $215M | 28 | Sell |
| WHWK | Whitehawk Therapeutics, Inc. | $263M | 32 | Sell |
| NAGE | Niagen Bioscience, Inc. | $260M | 38 | Hold |
| IMUX | Immunic, Inc. | $210M | 26 | Sell |
| ABEO | Abeona Therapeutics Inc. | $339M | 37 | Hold |
| IKT | Inhibikase Therapeutics, Inc. | $336M | 31 | Sell |
| NKTX | Nkarta, Inc. | $198M | 22 | Sell |
| EQ | Equillium, Inc. | $152M | 27 | Sell |
Peer medians: ROE -30.2% · P/E 27.0x · Gross margin 58.3%